Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Wallach

Ross

Naci

. FDA’s expedited approval programs: evidentiary standards, regulatory trade-offs, and potential improvements. Clin Trials, 2018; 3: 219–229.

US Food and Drug Administration. Kefauver-Harris amendments revolutionized drug development, https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm322856.htm (accessed 23 February 2018).

Federal Food, Drug, and Cosmetic Act. Chapter V. Section 505(d).

ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice. E6(R1). June 1996. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf

Biotechnology Innovation Organization. Clinical development success rates 2006–2015, 2016, https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf (2016, accessed 23 February 2018).

Killen

Harrington

Fauci

. MSM, AIDS research activism, and HAART. Lancet 2012; 380: 314–316.

Rose

Highland

Karafa

et al . Patient advocacy organizations, industry funding, and conflicts of interest. JAMA Intern Med 2017; 177: 344–350.

Schechter

Gutierrez

. Improving the quality of care for patients with cystic fibrosis. Curr Opin Pediatr 2010; 22: 296–301.

Sherman

Davies

Robb

et al . Accelerating development of scientific evidence for medical products within the existing US regulatory framework. Nat Rev Drug Discov 2017; 16: 297–298.

10.

Chou

Deyo

Devine

et al . The effectiveness and risks of long-term opioid treatment of chronic pain. Evidence Report/Technology Assessment 218, 2014. Rockville, MD: Agency for Healthcare Research and Quality.

11.

Le Noury

Nardo

Healy

et al . Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015; 351: h4320.

12.

Cipriani

Furukawa

Salanti

et al . Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. Epub ahead of print 20 February 2018. DOI: 10.1016/S0140-6736(17)32802.

13.

FDA-NIH Biomarker Working Group. BEST (biomarkers, endpoints, and other tools) resource. Silver Spring, MD: Food and Drug Administration, 2016.

14.

Fleming

DeMets

. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605–613.

15.

Ramsey

Nepom

Lonial

. Academic, foundation, and industry collaboration in finding new therapies. N Engl J Med 2017; 376: 1762–1769.

16.

Denny

Glazer

Grossman

et al . A data biosphere for biomedical research, https://medium.com/@benedictpaten/a-data-biosphere-for-biomedical-research-d212bbfae95d (2017, accessed 23 February 2018).

17.

Insel

. Digital phenotyping: technology for a new science of behavior. JAMA 2017; 318: 1215–1216.

18.

Sherman

Anderson

Dal Pan

et al . Real-world evidence—what is it and what can it tell us? N Engl J Med 2016; 375: 2293–2297.

19.

Shea

Ostermann

Hohman

et al . Regulatory watch: impact of breakthrough therapy designation on cancer drug development. Nat Rev Drug Discov 2016; 15: 152.

Expedited and facilitated drug evaluations and evidence of benefit and risk: The cup is half-full

Abstract

Get full access to this article

References